Howard Hughes Medical Institute

Hess Corporation Announces $50 Million Donation to Advance Salk Institute’s Harnessing Plants Initiative

Retrieved on: 
Monday, April 3, 2023
Environmental Health, Other Philanthropy, Research, Socially Responsible Investing, Environmental, Social and Governance (ESG), Climate Change, Commercial Building & Real Estate, Construction & Property, Environment, Other Energy, Finance, Utilities, Oil, Gas, Alternative Energy, Energy, Professional Services, Philanthropy, Other Natural Resources, Fund Raising, Science, Natural Resources, Computational biology, Genetics, Howard Hughes Medical Institute, Hess Corporation, Carbon, Hess, Plant, Climate change, Corporation, Soil, Jonas Salk, Professional corporation, Faculty, HPI, Botany, Health, NYSE, GameChanger, Forestry, Pharmaceutical industry, Renewable energy

In 2020, Hess donated $12.5 million to the Salk Institute’s Harnessing Plants Initiative to accelerate development of plant-based carbon capture and storage.

Key Points: 
  • In 2020, Hess donated $12.5 million to the Salk Institute’s Harnessing Plants Initiative to accelerate development of plant-based carbon capture and storage.
  • In 2021, Hess donated $3 million to establish the endowed Hess Chair in Plant Science at Salk.
  • “The Harnessing Plant Initiative is a potential gamechanger in tackling the global challenge of climate change,” CEO John Hess said.
  • We deeply appreciate the Hess Corporation for their continued generosity and partnership.”

Universal Medical (2666.HK) Announces 2022 Annual Results

Retrieved on: 
Wednesday, March 29, 2023
Health, Bed, Nephrology, Hospital, Oklahoma State University Medical Center, TCM, Howard Hughes Medical Institute, ROA, Profit margin, Ophthalmology, R, ROE, Cryptocurrency, Pharmaceutical industry, Nursing, Retail, Bank

HONG KONG, Mar 29, 2023 - (ACN Newswire) - Genertec Universal Medical Group Company Limited ("Universal Medical" or "Company"; Stock code: 2666.HK) is pleased to announce annual results for the year ended 31 December 2022.

Key Points: 
  • HONG KONG, Mar 29, 2023 - (ACN Newswire) - Genertec Universal Medical Group Company Limited ("Universal Medical" or "Company"; Stock code: 2666.HK) is pleased to announce annual results for the year ended 31 December 2022.
  • In 2022, Universal Medical adhered to the "Healthy China" strategy and continued to expand its footprint in the healthcare sector.
  • In 2022, the Company recorded a revenue of RMB11,912.1 million in total, up by 20.2% as compared to the previous year.
  • The number of beds of medical institutions that were included within the management system but not yet consolidated was over 2,000.

Cystic Fibrosis Foundation Announces Kathryn Brown as Next Chief Communications and Marketing Officer

Retrieved on: 
Wednesday, March 29, 2023
Research, Genetics, Philanthropy, Biotechnology, Health, Pharmaceutical, General Health, Foundation, Science, Valencia CF Foundation, Psychology, Journalism, University, Life, National academy, Marketing, HHMI, Communication, Scientific American, Biomedical Research, Howard Hughes Medical Institute, Cystic fibrosis, Medicine, Popular Science, The Conservation Fund, Genetic disorder, MD, Data, Cystic Fibrosis Foundation, CF, Social media, Management, Tourism

Today, the Cystic Fibrosis Foundation announced that Kathryn Brown will join the organization as its next Chief Communications and Marketing Officer.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced that Kathryn Brown will join the organization as its next Chief Communications and Marketing Officer.
  • She will oversee strategic communications and marketing across the Foundation, including initiatives to inform and engage the cystic fibrosis community, as it accelerates its mission to find a cure for the progressive, rare, genetic disorder.
  • Brown comes to the Foundation from the Howard Hughes Medical Institute (HHMI), a biomedical research and philanthropic organization, where she has served as Chief of Communications since 2017.
  • Brown will join the Cystic Fibrosis Foundation as Chief Communications and Marketing Officer on April 24, 2023.

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, March 21, 2023
Amgen, DNA, Novartis Institute for Tropical Diseases, Drug development, Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, CSO, Indian Institute of Science Education and Research, Thiruvananthapuram, Biotechnology, Howard Hughes Medical Institute, Research, Mount Sinai, Biomedical Research, Neuroscience, DSM-IV codes, Acquisition, Novartis, Patient, Hematology, Drug discovery, Cadent, Therapy, Stanley Center for Psychiatric Research at Broad Institute, Genome, Pharmaceutical industry, Beam, Sangamo Therapeutics

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).

Key Points: 
  • CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).
  • Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities.
  • Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
  • “We are thrilled to welcome Gopi to the Beam team during this exciting time as we advance our diverse clinical and earlier-stage pipeline of base editing programs,” said Dr. Ciaramella.

Dr. Maria Elena Bottazzi and Dr. Huda Zoghbi Inducted into the Texas Women's Hall of Fame at 2023 Gala

Retrieved on: 
Thursday, March 2, 2023
DRS, Quality of life, Woman, DSM-IV codes, Empowerment, Texas Women's Hall of Fame, Baylor College of Medicine, Mentorship, Hospital, Cerebellum, Baylor University, Rett syndrome, National school, Gene, Breakthrough Prize, Howard Hughes Medical Institute, Nobel Peace Prize, Texas Children's Hospital, COVID-19, Lone Star Distinguished Service Medal, Dysphagia, Neuron, Breakthrough Prize in Life Sciences, Commerce, Texas Women, Education, MECP2, Kavli Prize, SCA1, Tropical medicine, Nursing, Pharmaceutical industry, Fame

HOUSTON, March 2, 2023 /PRNewswire/ -- Texas Children's Hospital and Baylor College of Medicine are proud to announce that Drs. Maria Elena Bottazzi and Huda Zoghbi were honored today by the Greater Houston Women's Chamber of Commerce (GHWCC) and inducted into the Texas Women's Hall of Fame. The Texas Women's Hall of Fame recognizes outstanding women who have contributed significantly to the advancement of women and improved the quality of life for future generations of Texas women.

Key Points: 
  • Maria Elena Bottazzi and Huda Zoghbi were honored today by the Greater Houston Women's Chamber of Commerce (GHWCC) and inducted into the Texas Women's Hall of Fame.
  • The Texas Women's Hall of Fame recognizes outstanding women who have contributed significantly to the advancement of women and improved the quality of life for future generations of Texas women.
  • "It is a great honor to be inducted in the Texas Women's Hall of Fame", said Dr. Maria Elena Bottazzi.
  • "I am so honored to be named to the Texas Women's Hall of Fame along with so many other accomplished women in Houston.

Herbert Boyer, Pioneering Geneticist and Co-founder of Today's Biotech Industry, Joins GATC Health's Board of Advisors

Retrieved on: 
Thursday, March 2, 2023
Bacteria, Albany Medical Center Prize, Biotechnology, National Medal, Insulin, Protein, National Medal of Technology and Innovation, University, Roche, Genentech, Howard Hughes Medical Institute, Science, Drug discovery, Health, Therapy, Medical research, GATC, National Medal of Science, Artificial intelligence, Pharmaceutical industry, Medicine

IRVINE, Calif., March 2, 2023 /PRNewswire/ -- GATC Health Corp, a technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), announced that Herbert Boyer, internationally recognized biotechnology and genetic engineering innovator, has joined GATC Health's board of advisors. Mr. Boyer is credited with helping create the modern biotech industry when he co-founded Genentech in 1976 with Robert Swanson, a venture capitalist, when they each invested $500 to start the company. In 1980 Genentech was the first biotech company to go public and used the $45 million raised to build the company to over 15,000 employees today.

Key Points: 
  • In 1980 Genentech was the first biotech company to go public and used the $45 million raised to build the company to over 15,000 employees today.
  • "I have the opportunity to see many new biotechnology companies and their technologies' capabilities," said Mr. Boyer.
  • "I am very selective as to which companies I become associated with and am very excited about joining the team at GATC.
  • "We are extremely honored to welcome Mr. Boyer to the advisory board at GATC," stated Ian Jenkins, the company's Chief Science Officer.

Monod Bio Announces Publication in Nature Highlighting De Novo Protein Technology Platform for the Creation of Novel Luciferases

Retrieved on: 
Wednesday, February 22, 2023
Biotechnology, Technology, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Software, Genetics, Science, Clinical Trials, Monod, Protein, Paper, University, De novo protein structure prediction, De novo, University of Washington Department of Bioengineering, Algorithm, Howard Hughes Medical Institute, UW, Enzyme, University of Washington School of Medicine, Bio, Machine learning, Luciferin, Biochemistry, IPD, Luciferase, Rare-earth element, Fine chemical, Medicine, Nature

As reported in the journal Nature, a team based at the Institute for Protein Design (IPD) at UW Medicine devised machine-learning algorithms that can create light-emitting enzymes called luciferases.

Key Points: 
  • As reported in the journal Nature, a team based at the Institute for Protein Design (IPD) at UW Medicine devised machine-learning algorithms that can create light-emitting enzymes called luciferases.
  • Combining these biosensors with the de novo luciferases will create new commercial opportunities for Monod Bio.
  • “LuxSit and its underlying de novo protein design technology are fundamental to what we are developing at Monod Bio.
  • “We continue using LuxSit, machine learning, and de novo protein design to advance our unique biosensor pipeline aimed to improve human health.

Aera Therapeutics Launches with $193 Million in Financing to Enable and Advance the Next Generation of Transformative Genetic Medicines

Retrieved on: 
Thursday, February 16, 2023
Research, Genetics, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Messenger, MIT, Protein, James, Broad Institute, McGovern Institute for Brain Research, Tissue, Lux Capital, ARCH Venture Partners, Retrotransposon, Patient, Alnylam Pharmaceuticals, Harvard University, Howard Hughes Medical Institute, Liver, Doctor of Philosophy, GV, Therapy, Disease, Vertex Pharmaceuticals, RNA interference, Enzyme, PNP, Pharmaceutical industry, Vaccine, Management, Neuroscience

Aera Therapeutics announced its launch today with a vision to harness its proprietary delivery platform to unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas.

Key Points: 
  • Aera Therapeutics announced its launch today with a vision to harness its proprietary delivery platform to unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas.
  • The company has raised $193 million in combined Series A and B financings led by ARCH Venture Partners, GV and Lux Capital.
  • “Challenges remain with current delivery approaches, and genetic medicines applications have been generally restricted to the liver and ex vivo settings.
  • “Aera’s endogenous human PNP platform represents an exciting new approach for the delivery of genetic medicines.

Pennington Partners Launches Private Equity Platform, Announces Addition Of Greg DeNinno, CFA To Lead Pennington Private Access

Retrieved on: 
Thursday, February 2, 2023
Investment, Growth, HHMI, Goizueta Business School, Emory University, Pennington, Howard Hughes Medical Institute, American University, Public–Private Investment Program for Legacy Assets, International business, BSBA, Security (finance)

BETHESDA, Md., Feb. 2, 2023 /PRNewswire/ -- Pennington Partners, a multi-family investment office that specializes in working with entrepreneurs, CEOs / founders, and their families, has announced the launch of a new private equity platform, Pennington Private Access. This offering will build on the firm's award winning tax-advantaged alternatives platform, while widening exposure to private market investments. To lead the new practice, Pennington has also announced the addition of Greg DeNinno – an experienced institutional investor with strong relationships across the private equity industry.

Key Points: 
  • To lead the new practice, Pennington has also announced the addition of Greg DeNinno – an experienced institutional investor with strong relationships across the private equity industry.
  • As a firm, Pennington has unique capabilities to provide this expert level of guidance, selection, and access.
  • Brian Gaister, co-founder and CEO of Pennington Partners commented: "Greg is a fantastic addition to the Pennington team.
  • I am excited to join the team and lead the growth of Pennington Private Access.

Biotech Venture in the UAE Validated by IPO in the U.S.

Retrieved on: 
Tuesday, January 17, 2023
Nobel Prize, Cell, Nobel Prize in Physiology or Medicine, European Association of Science Editors, Therapy, The Coca-Cola Company, Rockefeller University, Biotechnology, Kraft Foods, IPO, WestView News, Drug discovery, Diet, Howard Hughes Medical Institute, Research, DRS, Doctor of Philosophy, United Arab Emirates, Pharmaceutical industry, Medical device, MD, Nestlé, Physiology, Medicine

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Disruptive platform biotechnology at the center of a Secondcell Bio biotech venture in the United Arab Emirates has been validated by an IPO filing in the United States.

Key Points: 
  • NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Disruptive platform biotechnology at the center of a Secondcell Bio biotech venture in the United Arab Emirates has been validated by an IPO filing in the United States.
  • The use of the technology in applications from natural flavors discovery to blocking pain illustrates the breadth and range of the multi-use discovery tool.
  • While Chromovert® was pioneered in the U.S., Dr. Shekdar is transitioning it to the UAE via his second company, Secondcell Bio.
  • "In the UAE, there is no legacy pharma industry, no dinosaurs to shove out of the way," says Dr. Shekdar.